Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CERC-006 in Adults with Complex Lymphatic Malformations
NCT04994002Phase 1Withdrawn
- Sponsor
- Avalo Therapeutics
- Start
- Sep 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of OSI-027 in Lymphatic Malformation (LM) (2 cohorts), sponsored by Avalo Therapeutics. Primary endpoint: Safety and Tolerability of CERC-006 up to 6 weeks. Planned start Sep 2021; status: withdrawn.
02
Drugs
OSI-027
03
Conditions
Lymphatic Malformation (LM)
Beyond the preview
Go deeper on NCT04994002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04994002.